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Abstract
While there is no known cure for HPV, prophylactic vaccination provides effective
method of primary prevention against HPV related diseases. However, many females
and males never receive the HPV vaccine as recommended. There are multiple barriers
to vaccination, and these barriers can be identified as parental, provider, or systemlevel. Understanding these barriers and developing strategies that provide accurate
information about HPV, its risks, and the need for vaccination are essential in the form
of sustained educational campaigns for parents, young adults, and providers.

INTRODUCTION

Human papillomavirus, or HPV, is the most common sexually
transmitted infection (STI) affecting both females and males in
the United States (US) [1]. HPV can infect the genital areas of
females and males including the skin of the vulva, penis, and anus;
the linings of the vagina, cervix, and rectum; and the linings of the
mouth and throat [2]. It is the cause of nearly all cases of cervical
cancer [3]. Unlike other STIs, most signs and symptoms of HPV
are nonexistent; therefore, most individuals are unaware of the
infection. Currently, approximately 79 million Americans are
infected with HPV and about 14 million people will become newly
infected each year [2]. Approximately 360,000 people develop
genital warts each year and more than 11,000 women develop
cervical cancer in the US as a result of HPV disease [2]. Even
though the rate of HPV infections is high, effective prevention
is available. HPV vaccines are safe, effective, and could prevent
the majority of HPV-attributable cancers, if vaccination coverage
is high [4]. Understanding the barriers to HPV vaccination and
providing education to overcome these barriers is essential.

HPV INFECTIONS

There are over 40 types of HPV that infect mucosal surfaces
and are sexually transmitted [5]. Despite the fact the immune
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system typically clears the virus from the body within two years;
some individuals will have a persistent HPV infection that can
cause various types of cancers and genital warts [6]. In fact,
most all cervical cancers are caused by HPV [7]. “Low-risk” HPV
types can cause warts on or around the genitals and anus of both
females and males [3,8] and can cause recurrent respiratory
papillomatosis, which is a rare growth of warts in the throat and
airway [8]. Females may also have warts on the cervix and in the
vagina. Because these genital HPV types rarely cause cancer, they
are called “low-risk” viruses [3,8]. “High-risk” HPV types cause
cancer [3]; 13 HPV types can cause cervical cancer [2]. Types
16 and 18 are the most oncogenic strains of the virus and are
responsible for causing over 75% of cases of cervical cancer and
the majority of other types of genital cancers [3,6]. When highrisk HPV lingers and infects the cells of the vulva, vagina, penis,
anus, or the oropharynx, it can cause cell changes or precancers
[1]. These precancers may eventually develop into cancer if
they’re not found and removed in time. These cancers are much
less common than cervical cancer. Much less is known about how
many people with HPV will develop cancer in these areas [1].

VACCINES

While there is no known cure for HPV, prophylactic vaccination
provides effective method of primary prevention against HPV
related diseases. The Advisory Committee for Immunization
Practices (ACIP), the CDC, and the ACS make recommendations
regarding vaccines. All three groups recommend routine HPV
vaccination for females and males ages 11 or 12 years and catchup vaccines for females through age 26 and for males through
age 21 [2,3,9]. The vaccine is also recommended for gay and
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bisexual males through age 26 and for females and males who
have compromised immune systems through age 26, if they did
not get fully vaccinated when they were younger [2].
Ideally, vaccination should occur before the first sexual
contact and prior to exposure to HPV; however, vaccination after
the first sexual contact is also recommended [7]. Young adult
females are of particular concern. The prevalence of HPV peaked
in females aged 20-24 years when nearly 45% of these females
were found to be infected [10]. Unfortunately, the statistics for
prevalence may not tell the true rate of occurrence. Since HPV
infections can clear quickly and go away on its own, the incidence
of HPV may be even higher than reported [2]. HPV is not curable,
but it is preventable [2]. Significant reductions in new infections
are possible and urgently needed. Routine HPV vaccination has
the potential to decrease the burden of HPV related diseases.

Three vaccines are available for HPV prevention and are
highly effective in preventing infection when given before initial
exposure to the virus. HPV vaccines work by stimulating the body
to produce antibodies that, in future encounters with HPV, bind
to the virus and prevent it from infecting cells [11]. Current HPV
vaccines use virus-like particles (VLPs) formed by HPV surface
components. VLPs lack the HPV virus DNA and are strongly
immunogenic, meaning the VLPs induce high levels of antibody
production making the vaccines highly effective [11].

In 2006, Gardasil® was approved by the US Food and Drug
Administration (FDA) as a quadrivalent vaccine (4vHPV) which
prevents HPV types 6, 11, 16, and 18 [12]. Another vaccine,
Cervarix®, was released in 2009 and is a bivalent vaccine (2vHPV)
that prevents HPV types 16 and 18, which can cause cervical
cancer and precancerous lesions [13]. In December 2014, the
FDA approved Gardasil 9® [9-valent human papillomavirus
vaccine (9vHPV)] for the prevention of diseases caused by nine
types of HPV: 6, 11, 16, 18, 31, 33, 45, 52, and 58 [12]. Gardasil
9® added protection against five additional types of HPV beyond
the quadrivalent vaccine; these additional types are responsible
for approximately 20% of cervical cancers that are not covered
by previously approved HPV vaccines [12]. Gardasil 9® is
approved for use in females ages 9-26 and in males ages 9-15.
Vaccination of females is recommended with 2vHPV, 4vHPV, or
9vHPV, and vaccination of males is recommended with 4vHPVor
9Vhpv [14]. The added benefit from 9vHPV will mostly benefit
females because it protects against the higher proportion of HPV
associated cancers for females; however, it is approved for males
as well as females [14]. Gardasil and Cervarix® provide nearly
100 percent protection against HPV types 16 and 18 and the
cervical cell changes that these persistent infections can cause
[11]. In studies, both Gardasil and Gardasil 9® were effective in
prevention of disease from the four shared HPV types (6,11,16,
and 18); Gardasil 9® was 97% effective in preventing cervical,
vulvar, and vaginal cancers caused the additional types added to
the vaccine [12].

FACTORS INFLUENCING VACCINATION

While most studies [15] have found positive attitudes towards
HPV vaccination, the percentage of females and males receiving
the vaccine in the US has been low. In 2012, 17 year old females
were the most highly vaccinated age group and only 44.5%
Clin Res Infect Dis 3(1): 1023 (2016)

received all three doses [16]. In 2013, only 36.9% of females aged
19–26 years reported receipt of ≥ 1 dose of HPV vaccine [17]. In
2014, coverage for all three doses was only 39.7% for females
13-17 years and 21.6% for males [18]. Most female adolescents
in commercial and Medicaid health plans are currently not
receiving the recommended doses of HPV vaccine by age 13
years [19]. Even those already exposed to HPV should still be
vaccinated. There are numerous types of HPV, and vaccination
after exposure will still protect against other strains during
future encounters, as cervical cancer is a result of persistent
infections with high-risk strains [10]. In addition to low uptake of
the HPV vaccine, it is equally concerning that young adults have
reported low intentions of receiving the vaccine [20,21]. Since
the first HPV vaccine was introduced in 2006, vaccine-type HPV
prevalence among young females decreased by 56% [6] but has
still not reached levels of other recommended vaccines [17].

Unfortunately, there are multiple barriers to vaccination
among females and males. These barriers can be identified as
parental, provider, or system-level. While parental consent
is not needed to vaccinate adolescents under 18 years of age,
adolescents typically seek approval [22]. Parents have reported
(a) lack of knowledge or needing more information before
vaccinating their children [4,22,23], (b) a concern about the
vaccine’s effect on sexual behavior [23], and (c) a concern about
the safety of the vaccine [15]. Parents also view their children
at low perceived risk of HPV infection and view vaccine costs/
financial concerns as barriers [23]. Parents have also voiced
concern about the safety of the HPV vaccine [15,24,25] but
not vaccination in general [24,25]. For parents of sons, lack
of vaccination was related to a perceived lack of direct benefit
[23]. Unfortunately there are social disparities for vaccine series
completion as well. Disproportionately more African American
females and males and females living below at or below the
poverty level have lower rates of series completion [16].
When vaccination does not occur before the age of 18,
barriers perceived by young adult females and males, aged 1926, becomes important. Lack of knowledge is a barrier to HPV
vaccine uptake [5,26,30]. Other barriers for young adults include
cost [5,23,31] safety of the vaccine [26,31,32], perceived low
susceptibility to HPV [5,28], low perceived benefits [33], and low
intention to receive the vaccine [21,31]. In particular, males are
less likely than females to receive the vaccine when they have to
pay for it, and females have more concerns about safety of the
vaccine than males [31].

A lack of provider recommendation was consistently found
to be a key barrier to increasing vaccination rates [4]. Health
care professionals may lack information on HPV vaccination [4].
Clinicians reported a lack of knowledge about the relationship
between HPV and urogenital or oral cancers [23]. Additionally,
providers reported recommending the vaccine only to select
populations rather than all 11 and 12 year olds [23]. Some
providers offered vaccination only to those they perceived as
high risk (often low income and/or patients of color) while others
reported only vaccinating older teens or females, but not males
[23]. Other providers recommend the vaccine more for females
than males [4]. Time was also a barrier; physicians reported that
discussing the HPV vaccine took more time than discussing the
other recommended vaccines for 11-12 year olds [4].
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System-level barriers include limited opportunities during a
provider visit to offer HPV vaccine and a lack of flexible tracking
and reminder capabilities for completion of the vaccine series
[4]. Another significant barrier is cost to patients and providers.
Providers consistently mentioned poor insurance coverage or
reimbursement and the costs to purchase and store the vaccine
as barriers [23].

METHODS TO PROMOTE VACCINATION

To overcome barriers to vaccination, health care providers
must recommend vaccination to parents of all 11 and 12 year
olds and before children become sexually active as part of
regular primary prevention interventions. Parents and providers
believe that preventing cancer is the most important reason to
vaccinate against HPV [34]. Parents consistently cited health
care provider recommendations as a key influencing factor in
their decision to vaccinate their children [23,25,32,34]. Parents
and young adults must also learn about the risk of HPV-related
infections and equate the vaccine as part of the social norm of
health care [32,34,35]. Providers should give clear and accessible
information and strongly recommend the vaccine as safe,
prevents cancer, and co-administer it with tetanus, diphtheria,
and acellular pertussis vaccine and quadrivalent meningococcal
conjugate vaccine [4,8,34]. Providers must help parents overcome
perceived distrust of the vaccine [8,15].
Additionally, system barriers must be addressed. Not only
is vaccine uptake important, providers must stress the need
to complete all three vaccinations. Innovative communication
reminders such as text messaging may lead to increased series
completion [23]. Providers must address disparities with
vaccination messages and focus on all 11 and 12 year olds.
Providers must take advantage of missed opportunities to
vaccinate when adolescents are seeking care within health care
systems [22,23] such as times when seeking physical exams
for athletics [23]. Systems must be developed to help providers
manage the additional costs associated with purchasing and
storing the vaccines.

Education about HPV and vaccination should vary slightly
for females and males. For females, genital HPV infections occur
mostly at a younger age and less commonly in females over 30
[2]. Certain types of sexual behavior increase a female’s risk of
getting an HPV infection; therefore, females must learn about the
risks of having sex at an early age, having multiple sex partners,
having a partner who has had many partners, and having sex
with uncircumcised males [3]. Since females have reported
more concerns about the safety or effectiveness of HPV vaccines,
interventions should focus more on reducing these barriers [3].
Educational campaigns should address the safety of the vaccine
and the need to return for all three doses [31].
For males, the main risk for an HPV infection is having
multiple sex partners. In addition, males who are not circumcised
are more likely to be infected and pass it on to their partners [3].
The reasons for this association are unclear. Circumcision does
not completely protect against HPV infection – circumcised males
can still get HPV and pass it on to their partners [3]. Education
content must emphasize the use of condoms for those who
are sexually active and the use of latex condoms the correct
Clin Res Infect Dis 3(1): 1023 (2016)

way every time they have sex. A condom can lower the risk of
getting HPV; but areas that are not covered by a condom can still
become infected [2]. Since cost is a greater barrier for males, cost
as a behavioral barrier should receive greater attention when
advocating HPV vaccination among males [31]. Messages could
be aimed at finding convenient times to receive the vaccine or
directing a patient to a clinic that offers the vaccine at a reduced
rate [26].

EDUCATIONAL CAMPAIGNS

Overall educational campaigns must address not only the
need to receive the initial vaccine but to return for the remaining
two dosages. Health care providers should institute reminder/
recall strategies for parents to bring their children back for all
dosages of the vaccine [8]. Providers must develop educational
programs that meet cultural and literacy needs unique to
patient populations [36]. For parents, educational campaigns
must address lack of knowledge in order to change parent’s
distrust of the HPV vaccine. Education campaigns should be
planned before school begins in the fall [24]. Even use of simple
educational pamphlets about HPV and HPV vaccination can
influence acceptance rates and are cost effective [25]. These
pamphlets must be made available in health care provider offices
and distributed at encounters within the health care system.
Acquiring tailored educational materials to meet the needs
of specific populations is important also, such as educational
materials in Spanish-language for Hispanic mothers who do not
speak English [25].
Vigorous marketing should target young adult females
and males. For females, a key message is to decrease cervical
cancer, and for males, a key message is to decrease anogential
cancer incidence for both genders [30]. For young adults,
emphasizing a disadvantage of not performing vaccination as a
health behavior (loss-framed message) has been shown to have
a greater persuasive advantage for females and males who want
to avoid the negative effects of HPV, such as cancer [31]. Thus,
educational messages must focus on the importance of receiving
the vaccine in order to prevent cancer and STIs. While listening
to professional lectures or receiving fact sheets for young adults
has shown mixed results in the literature [37,38], these strategies
should be continued as part of health education on college
campuses. These programs may lead to increased awareness
and uptake of the vaccine for those not vaccinated previously.
Additionally, emphasizing the severity of HPV related disease is
central to increasing regret if one does not get vaccinated and has
increased intention to seek vaccination [39]. Since college males
have been shown to be less knowledgeable about the existence
of the HPV vaccine, educational campaigns on college campuses
should increase awareness about the vaccine [15,28] and target
males in particular.
Safety of the HPV vaccine should be part of all educational
campaigns. Parents and young adults have voiced concerns
about the safety of the vaccine [15,16,31,32]. Research has
demonstrated that the 9vHPV is well tolerated with most adverse
events are localized with site-related pain, swelling, redness and
headaches [12,14], reactions not different from other vaccines.
Therefore, all educational campaigns must emphasize the safety
of HPV vaccination.
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CONCLUSION
HPV is so common that nearly all sexually active females
and males will develop an infection at some point in their lives
[2]. Since there is no one way to prevent infection from all the
different HPV types, there are effective strategies that can lower
the chances of becoming infected. Primary prevention strategies
about HPV, its risks, and the need for vaccination are essential in
the form of sustained educational campaigns for parents, young
adults, and providers. The burden of following these educational
campaigns falls on health care providers and those who interact
with larger populations of young adults, such as student health
services on college campuses. Special attention should be
provided to the social determinants of seeking vaccinations and
the system-level barriers that exist within the healthcare system.
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